Ascent Group LLC lowered its holdings in shares of MetLife, Inc. (NYSE:MET – Free Report) by 7.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,492 shares of the financial services provider’s stock after selling 2,206 shares during the period. Ascent Group LLC’s holdings in MetLife were worth $2,432,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. MeadowBrook Investment Advisors LLC boosted its stake in MetLife by 244.4% during the 3rd quarter. MeadowBrook Investment Advisors LLC now owns 310 shares of the financial services provider’s stock worth $26,000 after purchasing an additional 220 shares during the period. Carmichael Hill & Associates Inc. boosted its stake in MetLife by 131.9% during the 3rd quarter. Carmichael Hill & Associates Inc. now owns 327 shares of the financial services provider’s stock worth $27,000 after purchasing an additional 186 shares during the period. Wolff Wiese Magana LLC boosted its stake in MetLife by 374.3% during the 3rd quarter. Wolff Wiese Magana LLC now owns 351 shares of the financial services provider’s stock worth $29,000 after purchasing an additional 277 shares during the period. Peterson Financial Group Inc. acquired a new stake in MetLife during the 3rd quarter worth $30,000. Finally, Fortitude Family Office LLC boosted its stake in MetLife by 177.3% during the 3rd quarter. Fortitude Family Office LLC now owns 416 shares of the financial services provider’s stock worth $34,000 after purchasing an additional 266 shares during the period. Institutional investors and hedge funds own 89.81% of the company’s stock.
MetLife Stock Performance
NYSE:MET opened at $86.89 on Tuesday. The company has a current ratio of 0.16, a quick ratio of 0.16 and a debt-to-equity ratio of 0.51. The firm has a 50-day moving average price of $83.34 and a two-hundred day moving average price of $76.61. MetLife, Inc. has a twelve month low of $63.07 and a twelve month high of $89.05. The company has a market capitalization of $60.16 billion, a P/E ratio of 17.52, a price-to-earnings-growth ratio of 0.81 and a beta of 1.06.
MetLife Announces Dividend
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the stock. StockNews.com upgraded shares of MetLife from a “hold” rating to a “buy” rating in a research note on Monday, November 25th. Jefferies Financial Group raised their target price on shares of MetLife from $89.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, September 27th. TD Cowen raised their target price on shares of MetLife from $97.00 to $99.00 and gave the stock a “buy” rating in a research note on Wednesday, November 27th. Barclays reduced their target price on shares of MetLife from $91.00 to $90.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Finally, Wells Fargo & Company raised their target price on shares of MetLife from $92.00 to $93.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Fourteen research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $88.62.
Check Out Our Latest Stock Analysis on MetLife
About MetLife
MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.
Recommended Stories
- Five stocks we like better than MetLife
- Compound Interest and Why It Matters When Investing
- How to Master Trading Discipline: Overcome Emotional Challenges
- Stock Splits, Do They Really Impact Investors?
- Trump Tax Reforms: 7 Stocks That Could Benefit in 2025
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Stocks Near 52-Week Lows: Why They Could Be Smart Buys Today
Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.